Treatment of relapsed and refractory myeloma

Leukemia and Lymphoma

Volumn 49, Issue 8, 2008, Pages 1470-1485

  Reece, Donna E ^a   Leitch, Heather A ^b   Atkins, Harold ^c   Voralia, Michael ^d   Canning, Leah A ^e   LeBlanc, Richard ^f   Belch, Andrew R ^g   White, Darrell ^h   Kovacs, Michael J ⁱ  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e Kaleidoscope Strategic   (Canada)

^f LAVAL UNIVERSITY   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

^h DALHOUSIE UNIVERSITY   (Canada)

ⁱ UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Myeloma; Refractory; Relapsed

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; CARMUSTINE; CHLOROQUINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; MEPREDNISONE; MITOXANTRONE; PLACEBO; PREDNISONE; THALIDOMIDE; VALSPODAR; VERAPAMIL; VINCRISTINE; WARFARIN;

ANEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME DELETION 13; CHROMOSOME TRANSLOCATION 4; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CYTOGENETICS; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; EVIDENCE BASED MEDICINE; FATIGUE; GASTROINTESTINAL DISEASE; HEMORRHAGIC CYSTITIS; HUMAN; HYPERGLYCEMIA; INFECTION; INSOMNIA; LUNG EMBOLISM; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MONOTHERAPY; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW; SALVAGE THERAPY; SOMNOLENCE; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; WEAKNESS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MULTIPLE MYELOMA; PYRAZINES; SALVAGE THERAPY; THALIDOMIDE; TREATMENT OUTCOME;

EID: 51349125834     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802064941     Document Type: Review

References (132)

1. Canadian Cancer Society/National Cancer Institute of Canada: Canadian Cancer Statistics 2007 (2007)
2. Attal, M., Harousseau, J. L., Stoppa, A. M., Sotto, J. J., Fuzibet, J. G. Rossi, J. F. et al. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med, 335, pp. 91-97.
3. Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E. Hawkins, K. et al. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med, 348, pp. 1875-1883.
4. Berenson, J. R., Crowley, J. J., Grogan, T. M., Zangmeister, J., Briggs, A. D. Mills, G. M. et al. (2002) Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood, 99, pp. 3163-3168.
5. Attal, M., Harousseau, J. L., Leyvraz, S., Doyen, C., Hulin, C. Benboubker, L. et al. (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood, 108, pp. 3289-3294.
6. (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol, 16, pp. 3832-3842.
7. Facon, T., Mary, J. Y., Hulin, C., Benboubker, L., Attal, M. Pegourie, B. et al. (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet, 370, pp. 1209-1218.
8. Hulin, C., Facon, T., Rodon, P., Pegourie, B., Benboubker, L. Doyen, C. et al. (2007) Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients ≥75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. Blood (ASH Annual Meeting Abstracts), 110, p. 75.
9. San Miguel, J F, Schlag, R., Khuageva, N., Shpilberg, O., Dimopoulos, M. Kropff, M. et al. (2007) MMY-3002: A phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Blood (ASH Annual Meeting Abstracts), 110, p. 76.
10. Belch, A., Shelley, W., Bergsagel, D., Wilson, K., Klimo, P. White, D. et al. (1988) A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer, 57, pp. 94-99.
11. Alexanian, R., Gehan, E., Haut, A., Saiki, J. and Weick, J. (1978) Unmaintained remissions in multiple myeloma. Blood, 51, pp. 1005-1011.
12. Boccadoro, M., Palumbo, A., Bringhen, S., Merletti, F., Ciccone, G. Richiardi, L. et al. (2002) Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica, 87, pp. 846-850.
13. Kyle, R. A. (1982) Second malignancies associated with chemotherapeutic agents. Semin Oncol, 9, pp. 131-142.
14. Kyle, R. A., Gailani, S., Seligman, B. R., Blom, J., McIntyre, O. R. Pajak, T. F. et al. (1979) Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU. Cancer Treat Rep, 63, pp. 1265-1269.
15. Kyle, R. A., Seligman, B. R., Wallace Jr, H. J., Silver, R. T. and Glidewell, O. (1975) Holland JF. Mutiple myeloma resistant to melphalan (NSC-8806) treated with cyclophosphamide (NSC-26271), prednisone (NSC-10023), and chloroquine (NSC-187208). Cancer Chemother Rep, 59, pp. 557-562.
16. de Weerdt, O., van de Donk, N. W., Veth, G., Bloem, A. C., Hagenbeek, A. and Lokhorst, H. M. (2001) Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. Neth J Med, 59, pp. 50-56.
17. Lenhard, R. E., Daniels, M. J., Oken, M. M., Glick, J. H., Ettinger, D. S. Kalish, L. et al. (1994) An aggressive high dose cyclophosphamide and prednisone regimen for advanced multiple myeloma. Leuk Lymphoma, 13, pp. 485-489.
18. Wilson, K., Shelley, W., Belch, A., Brandes, L., Bergsagel, D. Klimo, P. et al. (1987) Weekly cyclophosphamide and alternate-day prednisone: An effective secondary therapy in multiple myeloma. Cancer Treat Rep, 71, pp. 981-982.
19. Brandes, L. J. and Israels, L. G. (1987) Weekly low-dose cyclophosphamide and alternate-day prednisone: An effective low toxicity regimen for advanced myeloma. Eur J Haematol, 39, pp. 362-368.
20. Trieu, Y., Trudel, S., Pond, G. R., Mikhael, J., Jaksic, W. Reece, D. E. et al. (2005) Weekly cyclophosphamide and alternate-day prednisone: An effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation. Mayo Clin Proc, 80, pp. 1578-1582.
21. Dalton, W. S., Crowley, J. J., Salmon, S. S., Grogan, T. M., Laufman, L. R. Weiss, G. R. et al. (1995) A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer, 75, pp. 815-820.
22. Mineur, P., Menard, J. F., Le Loet, X, Bernard, J. F., Grosbois, B. Pollet, J. P. et al. (1998) VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85). Br J Haematol, 103, pp. 512-517.
23. Friedenberg, W. R., Rue, M., Blood, E. A., Dalton, W. S., Shustik, C. Larson, R. A. et al. (2006) Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/ VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): A trial of the Eastern Cooperative Oncology Group. Cancer, 106, pp. 830-838.
24. Sonneveld, P., Suciu, S., Weijermans, P., Beksac, M., Neuwirtova, R. Solbu, G. et al. (2001) Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: An EORTC-HOVON randomized phase III study (06914). Br J Haematol, 115, pp. 895-902.
25. Phillips, J. K., Sherlaw-Johnson, C., Pearce, R., Davies, J. M., Reilly, J. T. Newland, A. C. et al. (1995) A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma. Leuk Lymphoma, 17, pp. 465-472.
26. Gertz, M. A., Kalish, L. A., Kyle, R. A., Hahn, R. G., Tormey, D. C. and Oken, M. M. (1995) Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol, 18, pp. 475-480.
27. Egerer, G., Hegenbart, U., Salwender, H., Haas, R., Hahn, U. Schmier, J. W. et al. (2001) Outpatient treatment of multiple myeloma with a combination of vincristine, adriamycin and dexamethasone. Support Care Cancer, 9, pp. 380-385.
28. Anderson, H., Scarffe, J. H., Ranson, M., Young, R., Wieringa, G. S. Morgenstern, G. R. et al. (1995) VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer, 71, pp. 326-330.
29. Alexanian, R., Barlogie, B. and Dixon, D. (1986) High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med, 105, pp. 8-11.
30. Lokhorst, H. M., Meuwissen, O. J., Bast, E. J. and Dekker, A. W. (1989) VAD chemotherapy for refractory multiple myeloma. Br J Haematol, 71, pp. 25-30.
31. Scheithauer, W., Cortelezzi, A., Kutzmits, R., Baldini, L. and Ludwig, H. (1987) VAD protocol for treatment of advanced refractory multiple myeloma. Blut, 55, pp. 145-152.
32. Palva, I. P., Ahrenberg, P., Ala Harja, K, Almqvist, A., Elonen, E. Hallman, H. et al. (1990) Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma. Finnish Leukaemia Group. Eur J Haematol, 44, pp. 121-124.
33. Browman, G. P., Belch, A., Skillings, J., Wilson, K., Bergsagel, D. Johnston, D. et al. (1992) Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: An NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group. Br J Haematol, 82, pp. 555-559.
34. Segeren, C. M., Sonneveld, P., van der Holt, B., Baars, J. W., Biesma, D. H. Cornellissen, J. J. et al. (1999) Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol, 105, pp. 127-130.
35. Jackson, D. V., Case, L. D., Pope, E. K., White, D. R., Spurr, C. L. Richards II, F. et al. (1985) Single agent vincristine by infusion in refractory multiple myeloma. J Clin Oncol, 3, pp. 1508-1512.
36. Alberts, D. S. and Salmon, S. E. (1975) Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: A pilot study. Cancer Chemother Rep, 59, pp. 345-350.
37. Bennett, J. M., Silber, R., Ezdinli, E., Levitt, M., Oken, M. Bakemeier, R. F. et al. (1978) Phase II study of adriamycin and bleomycin in patients with multiple myeloma. Cancer Treat Rep, 62, pp. 1367-1369.
38. Friedenberg, W. R., Kyle, R. A., Knospe, W. H., Bennett, J. M., Tsiatis, A. A. and Oken, M. M. (1991) High-dose dexamethasone for refractory or relapsing multiple myeloma. Am J Hematol, 36, pp. 171-175.
39. Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A. Facon, T. et al. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med, 352, pp. 2487-2498.
40. Richardson, P. G., Sonneveld, P., Schuster, M., Irwin, D., Stadtmauer, E. Facon, T. et al. (2007) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial. Blood, 110, pp. 3557-3560.
41. Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A. Stadtmauer, E. A. et al. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med, 357, pp. 2133-2142.
42. Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J. L. Dmoszynska, A. et al. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med, 357, pp. 2123-2132.
43. Gertz, M. A., Garton, J. P., Greipp, P. R., Witzig, T. E. and Kyle, R. A. (1995) A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia, 9, pp. 2115-2118.
44. Forgeson, G. V., Selby, P., Lakhani, S., Zulian, G., Viner, C. Maitland, J. et al. (1988) Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients. Br J Cancer, 58, pp. 469-473.
45. Alexanian, R., Yap, B. S. and Bodey, G. P. (1983) Prednisone pulse therapy for refractory myeloma. Blood, 62, pp. 572-577.
46. Lee, C. K., Barlogie, B., Munshi, N., Zangari, M., Fassas, A. Jacobson, J. et al. (2003) DTPACE: An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol, 21, pp. 2732-2739.
47. Munshi, N., Desikan, K., Jagannath, S., Siegel, D., Bracy, D. Tricot, G. et al. (1996) Dexamethasone, cyclophosphamide, etoposide and cis-platinum (DCEP), an effective regimen for relapse after high-dose chemotherapy and autologous transplantation (AT). Blood (ASH Annual Meeting Abstracts), 88, p. 2331.
48. Gerrie, A. S., Xu, W., Fung, S., Stewart, A. K., Reece, D. Trudel, S. et al. (2007) Retrospective review of DPACE therapy for aggressive, refractory multiple myeloma (MM). J Clin Oncol (ASCO Annual Meeting Abstracts), 25, p. 18500.
49. McBride, W. (1961) Thalidomide and congenital abnormalities. Lancet, 2, p. 1358.
50. Parman, T., Wiley, M. J. and Wells, P. G. (1999) Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med, 5, pp. 582-585.
51. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P. Eddlemon, P. et al. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 341, pp. 1565-1571.
52. Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J. Munshi, N. et al. (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood, 98, pp. 492-494.
53. Glasmacher, A., Hahn, C., Hoffmann, F., Naumann, R., Goldschmidt, H. von Lilienfeld-Toal, M. et al. (2006) A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol, 132, pp. 584-593.
54. Prince, H. M., Schenkel, B. and Mileshkin, L. (2007) An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma, 48, pp. 46-55.
55. Yakoub-Agha, I., Doyen, C., Hulin, C., Marit, G., Voillat, L. Grosbois, B. et al. (2006) A multicenter prospective randomized study testing non-inferiority of thalidomide 100 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: Results of the final analysis of the IFM 01-02 study. J Clin Oncol (ASCO Annual Meeting Abstracts), 24, p. 7520.
56. Neben, K., Moehler, T., Benner, A., Kraemer, A., Egerer, G. Ho, A. D. et al. (2002) Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res, 8, pp. 3377-3382.
57. Mileshkin, L., Biagi, J. J., Mitchell, P., Underhill, C., Grigg, A. Bell, R. et al. (2003) Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: Adverse prognostic impact of advanced age. Blood, 102, pp. 69-77.
58. Schey, S. A., Cavenagh, J., Johnson, R., Child, J. A., Oakervee, H. and Jones, R. W. (2003) An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk Res, 27, pp. 909-914.
59. Waage, A., Gimsing, P., Juliusson, G., Turesson, I., Gulbrandsen, N. Eriksson, T. et al. (2004) Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. Br J Haematol, 125, pp. 149-155.
60. Tosi, P., Zamagni, E., Cellini, C., Ronconi, S., Patriarca, F. Ballerini, F. et al. (2002) Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica, 87, pp. 408-414.
61. Hus, M., Dmoszynska, A., Soroka-Wojtaszko, M., Jawniak, D., Legiec, W. Ciepnuch, H. et al. (2001) Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica, 86, pp. 404-408.
62. Kumar, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Geyer, S. M. Iturria, N. L. et al. (2003) Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc, 78, pp. 34-39.
63. Richardson, P., Schlossman, R., Jagannath, S., Alsina, M., Desikan, R. Blood, E. et al. (2004) Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc, 79, pp. 875-882.
64. Fermand, J-P, Jaccard, A., Macro, M., Uzunhan, Y., Allard, C. Castaigne, S. et al. (2006) A randomized comparison of dexamethasone + thalidomide (Dex/Thal) vs. Dex + placebo (Dex/P) in patients (pts) with relapsing multiple myeloma (MM). Blood, 108, p. 3563.
65. Palumbo, A., Giaccone, L., Bertola, A., Pregno, P., Bringhen, S. Rus, C. et al. (2001) Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica, 86, pp. 399-403.
66. Murakami, H., Handa, H., Abe, M., Iida, S., Ishii, A. Ishikawa, T. et al. (2007) Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. Eur J Haematol, 79, pp. 234-239.
67. Dimopoulos, M. A., Zervas, K., Kouvatseas, G., Galani, E., Grigoraki, V. Kiamouris, C. et al. (2001) Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol, 12, pp. 991-995.
68. Terpos, E., Mihou, D., Szydlo, R., Tsimirika, K., Karkantaris, C. Politou, M. et al. (2005) The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia, 19, pp. 1969-1976.
69. Palumbo, A., Bertola, A., Falco, P., Rosato, R., Cavallo, F. Giaccone, L. et al. (2004) Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J, 5, pp. 318-324.
70. Palumbo, A., Falco, P., Ambrosini, M. T., Petrucci, M. T., Musto, P. Caravita, T. et al. (2005) Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant. Eur J Haematol, 75, pp. 391-395.
71. Garcia-Sanz, R., Gonzalez-Porras, J. R., Hernandez, J. M., Polo-Zarzuela, M., Sureda, A. Barrenetxea, C. et al. (2004) The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia, 18, pp. 856-863.
72. Kropff, M. H., Lang, N., Bisping, G., Domine, N., Innig, G. Hentrich, M. et al. (2003) Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol, 122, pp. 607-616.
73. Moehler, T. M., Neben, K., Benner, A., Egerer, G., Krasniqi, F. Ho, A. D. et al. (2001) Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood, 98, pp. 3846-3848.
74. Dimopoulos, M. A., Hamilos, G., Zomas, A., Gika, D., Efstathiou, E. Grigoraki, V. et al. (2004) Pulsed cyclophosphamide, thalidomide and dexamethasone: An oral regimen for previously treated patients with multiple myeloma. Hematol J, 5, pp. 112-117.
75. Kyriakou, C., Thomson, K., D'Sa, S., Flory, A., Hanslip, J. Goldstone, A. H. et al. (2005) Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol, 129, pp. 763-770.
76. Offidani, M., Corvatta, L., Marconi, M., Visani, G., Alesiani, F. Brunori, M. et al. (2006) Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: A prospective, multicenter, phase II study. Haematologica, 91, pp. 133-136.
77. Hussein, M. A., Baz, R., Srkalovic, G., Agrawal, N., Suppiah, R. Hsi, E. et al. (2006) Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc, 81, pp. 889-895.
78. Hovenga, S., Daenen, S. M., de Wolf, J. T., van Imhoff, G. W., Kluin-Nelemans, H. C. Sluiter, W. J. et al. (2005) Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: A prospective phase II study. Ann Hematol, 84, pp. 311-316.
79. Suvannasankha, A., Fausel, C., Juliar, B. E., Yiannoutsos, C. T., Fisher, W. B. Ansari, R. H. et al. (2007) Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21. Oncologist, 12, pp. 99-106.
80. Palumbo, A., Avonto, I., Bruno, B., Ambrosini, M. T., Bringhen, S. Cavallo, F. et al. (2006) Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Eur J Haematol, 76, pp. 273-277.
81. Offidani, M., Corvatta, L., Marconi, M., Olivieri, A., Catarini, M. Mele, A. et al. (2004) Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. Hematol J, 5, pp. 312-317.
82. Offidani, M., Bringhen, S., Corvatta, L., Falco, P., Marconi, M. Avonto, I. et al. (2007) Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: A case-matched study in advanced multiple myeloma. Eur J Haematol, 78, pp. 297-302.
83. Wulff, C. H., Hoyer, H., Asboe-Hansen, G. and Brodthagen, H. (1985) Development of polyneuropathy during thalidomide therapy. Br J Dermatol, 112, pp. 475-480.
84. Mileshkin, L., Stark, R., Day, B., Seymour, J. F., Zeldis, J. B. and Prince, H. M. (2006) Development of neuropathy in patients with myeloma treated with thalidomide: Patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol, 24, pp. 4507-4514.
85. Tosi, P., Zamagni, E., Cellini, C., Plasmati, R., Cangini, D. Tacchetti, P. et al. (2005) Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol, 74, pp. 212-216.
86. Cibeira, M. T., Rosinol, L., Ramiro, L., Esteve, J., Torrebadell, M. and Blade, J. (2006) Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. Eur J Haematol, 77, pp. 486-492.
87. Ikhlaque, N., Seshadri, V., Kathula, S. and Baumann, M. A. (2006) Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol, 81, pp. 420-422.
88. Minnema, M. C., Breitkreutz, I., Auwerda, J. J., van der Holt, B., Cremer, F. W. van Marion, A. M. et al. (2004) Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia, 18, pp. 2044-2046.
89. Baz, R., Li, L., Kottke-Marchant, K., Srkalovic, G., McGowan, B. Yiannaki, E. et al. (2005) The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc, 80, pp. 1568-1574.
90. Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D. Richardson, P. G. et al. (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol, 127, pp. 165-172.
91. Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S. Irwin, D. et al. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med, 348, pp. 2609-2617.
92. Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S. Irwin, D. H. et al. (2006) Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: Final time-to-event results from the SUMMIT trial. Cancer, 106, pp. 1316-1319.
93. Orlowski, R. Z., Nagler, A., Sonneveld, P., Blade, J., Hajek, R. Spencer, A. et al. (2007) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression. J Clin Oncol, 25, pp. 3892-3901.
94. Harousseau, J. L., Nagler, A., Sonneveld, P., Blade, J., Hajek, R. Spencer, A. et al. (2007) Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone. J Clin Oncol (ASCO Annual Meeting Abstracts), 25, p. 8002.
95. Kropff, M., Bisping, G., Schuck, E., Liebisch, P., Lang, N. Hentrich, M. et al. (2007) Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol, 138, pp. 330-337.
96. Berenson, J. R., Yang, H. H., Sadler, K., Jarutirasarn, S. G., Vescio, R. A. Mapes, R. et al. (2006) Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol, 24, pp. 937-944.
97. Palumbo, A., Ambrosini, M. T., Benevolo, G., Pregno, P., Pescosta, N. Callea, V. et al. (2007) Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood, 109, pp. 2767-2772.
98. Suvannasankha, A., Smith, G. G., Juliar, B. E. and Abonour, R. (2006) Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma. Clin Lymphoma Myeloma, 7, pp. 131-134.
99. Berenson, J. R., Matous, J., Swift, R. A., Mapes, R., Morrison, B. and Yeh, H. S. (2007) A phase I/II study of arsenic trioxide/bortezomib/ ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res, 13, pp. 1762-1768.
100. Sonneveld, P., Richardson, P. G., Schuster, M. W., Irwin, D., Stadtmauer, E. A. Facon, T. et al. (2005) Bortezomib is more effective than high-dose dexamethasone at first relapse and provides better outcomes when used early rather than as later salvage therapy in relapsed multiple myeloma. Haematologica (10th Congress of the European Hematology Association), 90, p. 400.
101. Richardson, P. G., Briemberg, H., Jagannath, S., Wen, P. Y., Barlogie, B. Berenson, J. et al. (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol, 24, pp. 3113-3120.
102. Mulkerin, D., Remick, S., Ramanathan, R., Hamilton, A., Takimoto, C. Davies, A. et al. (2006) A dose-escalating and pharmacologic study of bortezomib in adult cancer patients with impaired renal function. J Clin Oncol (ASCO Annual Meeting Abstracts), 24, p. 2032.
103. Jagannath, S., Barlogie, B., Berenson, J. R., Singhal, S., Alexanian, R. Srkalovic, G. et al. (2005) Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer, 103, pp. 1195-1200.
104. Chanan-Khan, A. A., Kaufman, J. L., Mehta, J., Richardson, P. G., Miller, K. C. Lonial, S. et al. (2007) Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study. Blood, 109, pp. 2604-2606.
105. Berenson, J. R., Jagannath, S., Barlogie, B., Siegel, D. T., Alexanian, R. Richardson, P. G. et al. (2005) Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer, 104, pp. 2141-2148.
106. Druck, M., Walters, I. B., Carloss, H., Sood, R., Leblanc, A. L. and Noga, S. J. (2006) A phase IV, open-label trial using bortezomib for retreatment of patients (pts) with multiple myeloma (MM) following an initial response to bortezomib. J Clin Oncol (ASCO Annual Meeting Abstracts), 24, p. 17539.
107. Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A. Facon, T. et al. (2007) Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol, 137, pp. 429-435.
108. San Miguel, J F, Hajek, R., Nagler, A., Sonneveld, P., Spencer, A. Blade, J. et al. (2007) Doxil + velcade in previously treated ≥65Y myeloma pts. Haematologica (XIth International Myeloma Workshop Meeting Abstracts), 92, p. 620.
109. Spencer, A., Hajek, R., Nagler, A., Sonneveld, P., Blade, J. Robak, T. et al. (2007) Doxil + velcade in previously treated high risk myeloma. Haematologica (XIth International Myeloma Workshop Meeting Abstracts), 92, p. 629.
110. Jagannath, S., Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D. Stadtmauer, E. A. et al. (2007) Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia, 21, pp. 151-157.
111. Chang, H., Trieu, Y., Qi, X., Xu, W., Stewart, K. A. and Reece, D. (2007) Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res, 31, pp. 779-782.
112. Sagaster, V., Ludwig, H., Kaufmann, H., Odelga, V., Zojer, N. Ackermann, J. et al. (2007) Bortezomib in relapsed multiple myeloma: Response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia, 21, pp. 164-168.
113. Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R. Alsina, M. et al. (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 108, pp. 3458-3464.
114. Baz, R., Walker, E., Karam, M. A., Choueiri, T. K., Jawde, R. A. Bruening, K. et al. (2006) Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: Safety and efficacy. Ann Oncol, 17, pp. 1766-1771.
115. Chanan-Khan, A. A., Weber, D., Dimopoulos, M., Chen, C., Niesvizky, R. Wang, M. et al. (2006) Lenalidomide (L) in combination with dexamethasone (D) improves survival and time to progression in elderly patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM). Blood, 108, p. 3551.
116. Niesvizky, R., Martinez-Banos, D., Jalbrzikowski, J., Christos, P., Furst, J. De Sancho, M. et al. (2007) Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma, 48, pp. 2330-2337.
117. Bahlis, N. J., Song, K., Trieu, Y., Roland, B., Masih-Khan, E. Chang, H. et al. (2007) Lenalidomide overcomes poor prognosis conferred by del13q and t(4;14) but Not del17p13 in multiple myeloma: Results of the Canadian MM016 trial. Blood, 110, p. 3597.
118. Sirohi, B., Powles, R., Singhal, S., Treleaven, J., Kulkami, S. Sankpal, S. et al. (2002) Second high-dose melphalan autografts for myeloma patients relapsing after one autograft: Results equivalent to tandem transplantation. Bone Marrow Transplant (EBMT Annual Meeting Abstracts) (abstr 121), 29, p. 121.
119. Mikhael, J. R., Samiee, S., Stewart, A. K., Chen, C., Trudel, S. Franke, N. et al. (2004) Outcome after second autologous stem cell transplantation as salvage therapy in patients with relapsed multiple myeloma. Blood, 104, p. 943.
120. Vogl, D. T., Stadtmauer, E., Richardson, P. G., Sonneveld, P., Schuster, M. W. Irwin, D. et al. (2006) Impact of prior autologous stem cell transplant (ASCT) in patients receiving bortezomib or dexamethasone for relapsed/refractory multiple myeloma in the APEX trial. J Clin Oncol (ASCO Annual Meeting Abstracts), 24, p. 7546.
121. Chanan-Khan, A. A., Yu, Z., Weber, D., Chen, C., Niesvizky, R. Spencer, A. et al. (2006) Lenalidomide (L) in combination with dexamethasone (D) significantly improves time to progression (TTP) in non-stem cell transplant patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM): Analysis from MM-009 and MM-010 randomized phase III clinical trials. Blood, 108, p. 3554.
122. Nagler, A., Hajek, R., Sonneveld, P., Spencer, A., Blade, J. Robak, T. et al. (2007) Doxil + velcade in previously treated myeloma w/prior SCT. Haematologica (XIth International Myeloma Workshop Meeting Abstracts), 92, p. 625.
123. Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R. and Greipp, P. R. (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol, 24, pp. 431-436.
124. Rajkumar, S. V., Hussein, M., Catalano, L., Jedrzejcak, W., Sirkovich, S. Olesnyckyj, M. et al. (2006) A multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol (ASCO Annual Meeting Abstracts), 24, p. 7517.
125. Zervas, K., Mihou, D., Katodritou, E., Pouli, A., Mitsouli, C. H. Anagnostopoulos, A. et al. (2007) VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: Results of a multicenter randomized trial of the Greek Myeloma Study Group. Ann Oncol, 18, pp. 1369-1375.
126. Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Caparella, V. Callea, V. et al. (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet, 367, pp. 825-831.
127. Sonneveld, P., Hajek, R., Nagler, A., Spencer, A., Blade, J. Robak, T. et al. (2007) Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/ refractory multiple myeloma (RRMM). J Clin Oncol (ASCO Annual Meeting Abstracts), 25, p. 8023.
128. Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E. van Rhee, F. et al. (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med, 354, pp. 1021-1030.
129. Wang, M., Knight, R., Dimopoulos, M., Siegel, D., Rajkumar, S. V. Facon, T. et al. (2006) Lenalidomide in combination with dexamethasone was more effective than dexamethasone in patients who have received prior thalidomide for relapsed or refractory multiple myeloma. Blood, 108, p. 3553.
130. Kumar, S. K., Therneau, T. M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A. Rajkumar, S. V. et al. (2004) Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc, 79, pp. 867-874.
131. Niesvizky, R., Richardson, P. G., Sonneveld, P., Schuster, M. W., Coleman, M. Irwin, D. et al. (2006) Relationship between quality of response to bortezomib (btz) and clinical benefit in multiple myeloma (MM) in the APEX and SUMMIT studies. Blood, 108, p. 3529.
132. Harousseau, J. L., Weber, D., Dimopoulos, M., Olesnyckyj, M., Yu, Z. Zeldis, J. et al. (2007) Relapsed/refractory multiple myeloma patients